Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00326586 | A Phase I Dose-Escalation Study of BMS-641988 in Patients With Castration-Resistant Prostate Cancer | PHASE1 | COMPLETED | 54 | — | — | May 1, 2006 | Mar 1, 2009 | Jan 25, 2011 | 3 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AR Antagonist (BMS-641988) | DRUG | Tablets, Oral, 6 Patients will be randomized in a 1:1 ratio and in a double-blinded fashion to achieve a single dose of the study drug or Placebo on C1D1. Once daily, at least 3 cycles until the disease progresses |
Inclusion Criteria: * Advanced castration-resistant prostate carcinoma with progressive disease * At least 4 weeks must have elapsed from major surgery * Patient must be available for follow-up * Adequate liver and kidney function * Adequate blood values Exclusion Criteria: * Uncontrolled or sign...